NASDAQ:CPRX - Catalyst Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.90 0.00 (0.00 %) (As of 08/19/2018 03:30 PM ET)Previous Close$2.90Today's Range$2.8750 - $2.970152-Week Range$2.18 - $4.51Volume287,518 shsAverage Volume662,673 shsMarket Capitalization$304.72 millionP/E Ratio-13.81Dividend YieldN/ABeta1.2 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida. Receive CPRX News and Ratings via Email Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:CPRX CUSIPN/A Webwww.catalystpharma.com Phone305-420-3200 Debt Debt-to-Equity RatioN/A Current Ratio22.43 Quick Ratio22.43 Price-To-Earnings Trailing P/E Ratio-13.81 Forward P/E Ratio-9.35 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book Value$0.79 per share Price / Book3.67 Profitability EPS (Most Recent Fiscal Year)($0.21) Net Income$-18,410,000.00 Net MarginsN/A Return on Equity-32.67% Return on Assets-31.06% Miscellaneous Employees21 Outstanding Shares102,600,000Market Cap$304.72 million Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) issued its earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. View Catalyst Pharmaceuticals' Earnings History. When is Catalyst Pharmaceuticals' next earnings date? Catalyst Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, November, 14th 2018. View Earnings Estimates for Catalyst Pharmaceuticals. What price target have analysts set for CPRX? 5 Wall Street analysts have issued 1-year price objectives for Catalyst Pharmaceuticals' shares. Their predictions range from $5.00 to $8.00. On average, they anticipate Catalyst Pharmaceuticals' stock price to reach $6.20 in the next year. This suggests a possible upside of 113.8% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals. What is the consensus analysts' recommendation for Catalyst Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals. What are Wall Street analysts saying about Catalyst Pharmaceuticals stock? Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock: 1. According to Zacks Investment Research, "Catalyst reported narrower-than-expected loss in the second quarter of 2018. The company resubmitted the new drug application (NDA) of Firdapse for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in March 2018. The FDA accepted the NDA and granted Priority Review to the same in May 2018. The FDA has set an action date of Nov 28, 2018. A potential approval will boost the growth prospects. The company is also actively engaged in pre-commercialization activities for a potential launch of the drug. Meanwhile, the company is also developing Firdapse for additional indications. However, Catalyst has a limited number of candidates in its pipeline and is highly dependent on the FDA’s approval of the drug for growth. The company’s share price movement shows that the stock has underperformed the industry year to date." (8/13/2018) 2. HC Wainwright analysts commented, "Our price target of $6/share is based on an equally weighted composite of: (a) $7.18/ share, as a 35x multiple of taxed and diluted 2024 GAAP EPS of $0.61 discounted back to 2018 at 20%; and (b) an NPV of discounted cash flows between 2018-2024 of $7.18/share (discount rate 12%, growth rate 2%)." (8/9/2018) Who are some of Catalyst Pharmaceuticals' key competitors? Some companies that are related to Catalyst Pharmaceuticals include TherapeuticsMD (TXMD), Eagle Pharmaceuticals (EGRX), Athenex (ATNX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Vanda Pharmaceuticals (VNDA), Endocyte (ECYT), Zai Lab (ZLAB), Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Rhythm Pharmaceuticals (RYTM), Retrophin (RTRX), Apellis Pharmaceuticals (APLS), Radius Health (RDUS) and Assembly Biosciences (ASMB). Who are Catalyst Pharmaceuticals' key executives? Catalyst Pharmaceuticals' management team includes the folowing people: Mr. Patrick J. McEnany, Co-Founder, Chairman, CEO & Pres (Age 71)Ms. Alicia Grande, VP, CFO & Treasurer (Age 47)Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 56)Mr. Brian Elsbernd, Sr. VP of Legal & Compliance (Age 54)Dr. Gary Ingenito, Chief Medical Officer (Age 62) Has Catalyst Pharmaceuticals been receiving favorable news coverage? Press coverage about CPRX stock has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a news and rumor sentiment score of 0.11 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.87 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for Catalyst Pharmaceuticals. Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.91%), Baker BROS. Advisors LP (3.53%), Millennium Management LLC (1.57%), JBF Capital Inc. (0.50%), GSA Capital Partners LLP (0.37%) and Bank of New York Mellon Corp (0.27%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals. Which major investors are selling Catalyst Pharmaceuticals stock? CPRX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Baker BROS. Advisors LP, Alps Advisors Inc. and Alps Advisors Inc.. View Insider Buying and Selling for Catalyst Pharmaceuticals. Which major investors are buying Catalyst Pharmaceuticals stock? CPRX stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., GSA Capital Partners LLP, Millennium Management LLC, Acadian Asset Management LLC, MetLife Investment Advisors LLC, JBF Capital Inc., Bank of New York Mellon Corp and Lido Advisors LLC. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $2.90. How big of a company is Catalyst Pharmaceuticals? Catalyst Pharmaceuticals has a market capitalization of $304.72 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected] MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 293 (Vote Outperform)Underperform Votes: 143 (Vote Underperform)Total Votes: 436MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/19/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?